UNSPSC 51161702: Beractant

This classification denotes a respiratory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S866O45PIG.The European Medicines Agency schedules Beractant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13043MIG. As of Q4 2014, BERACTANT remains the US FDA Preferred Term for this commodity.

UNSPSC 51161702 Beractant is a Commodity code that, based on recent state and local opportunities, encompasses pharmaceutical procurement and pharmacy services delivery rather than the narrow beractant surfactant product alone. State and local governments are using this code to solicit naloxone products, drug deactivation systems, and comprehensive on-site pharmacy services for county health centers and employee health plans. Issuing bodies include county governments operating public health clinics and administering group health benefits for employees and retirees. The work ranges from transactional product procurement with quarterly delivery requirements to managed pharmacy services contracts involving formulary management, dispensing, billing administration, and cost containment for defined populations.

Recent activity spans Florida and Georgia. Seminole County, Florida released an IFB on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023, with quarterly deliveries to the county health building and FEMA compliance required). Hall County, Georgia issued an RFQ/P on May 4, 2026, for on-site pharmacy services at its Family Health Center Clinic in Gainesville, serving approximately 3,005 eligible individuals across multiple insurance plan types, with an 80/20 technical-to-cost scoring structure, responses due June 4, 2026, and a one-year initial term beginning January 1, 2027, with four optional one-year renewals. Both opportunities required E-Verify compliance and standard commercial insurance; neither specified set-aside designations.